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Fever is responsible for up to 80% of all pediatric
(<5 years of age) outpatient visits in Sub-Saharan Africa.
Even in highly endemic areas, malaria rarely causes more
than 30% of cases1. The remaining episodes are pre-
sumably of viral origin but are rarely documented as such.
Recent outbreaks due to the Zika, Chikungunya, and
Yellow fever viruses have provided an urgent incentive
to better identify these fevers’ etiologies. Unbiased high-
throughput screening has allowed the discovery of
unexpected viral infections, such as those not previously
considered to be human pathogens or strains that are too
genetically divergent to be recognized by conventional
targeted screening methods. These advances have also
identiﬁed the importance of “commensal” organisms,
including viruses, that may signiﬁcantly impact health and
disease. Next-generation sequencing (NGS) is one of the
most powerful tools in this new wave of pathogen dis-
covery, providing high-resolution nuances to human
pathogenomic diversity.
Using this approach in pediatric samples from an out-
patient clinic in urban Tanzania, we describe the presence
of the novel human astroviruses, (HAstV)-MLB1 and
MLB2, in two patients with different clinical outcomes.
HAstV-MLB1 and MLB2 were discovered in the late
2000s from human stool samples and are considered to be
novel HAstV as they are highly divergent from classical
HAstV (serotypes HAstV-1 to 8)2. In contrast to classical
HAstV, a major cause of gastroenteritis3,4, the disease
spectrum associated with these novel HAstV remains to
be characterized5,6. Recent ﬁndings suggest that suscep-
tible populations to novel HAstV complications include
immunocompromised and pediatric ≤ 4-years patients7.
However, without routine screening, deﬁnitive conclu-
sions remain impossible. A previous seroprevalence study
revealed a particularly high occurrence of HAstV-MLB1
among children, suggesting that primary infection occurs
during childhood8. Both HAstV-MLB1 and MLB2 have
rarely been detected outside the gastrointestinal tract. To
date, HAstV-MLB2 infection has been found in plasma
and nasopharyngeal swabs from two febrile children9,10
and in the cerebrospinal ﬂuid of two adult patients (one of
whom was immunocompromised)11. By contrast, HAstV-
MLB1 has only been reported outside the gastrointestinal
tract in a 4-year-old immunocompromised patient with
disseminated infection12.
Here, we report the results of two novel HAstV infec-
tion cases in individuals who were part of a large pediatric
cohort (2 months–5 years of age) recruited at nine out-
patient clinics in Dar es Salaam, Tanzania. Unbiased NGS
was performed on 135 serum samples collected between
December 2014 and February 2016. The samples were
selected randomly from a cohort presenting with either
“fever without a clinical focus” or “severe febrile disease
requiring hospital referral”. Participants in this study were
malaria-negative by rapid diagnostic testing and were
managed by electronic clinical algorithms13. RNA and
DNA libraries were prepared as previously described14 for
analysis by NGS paired-end sequencing using the 100-bp
protocol. The HiSeq 2500 and 4000 platforms (Illumina,
San Diego, US) were used for RNA and DNA,
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respectively, generating an average of 96 million reads per
sample. Raw data were analyzed using an updated version
of the ezVIR pipeline14.
Novel HAstV were detected in two patients (raw data
available here: https://doi.org/10.5281/zenodo.1094970),
Case #1 (158 HAstV-MLB1 reads, genome coverage=
29.54%) and #2 (459 HAstV-MLB2 reads, genome cov-
erage= 95.83%) (Fig. 1 and Supplementary Figure S1).
Each case’s clinical presentation is summarized below.
Case #1: a 9-month-old male presented with a 3-day
history of fever (axillary temperature of 37.6 °C) and no other
complaints or signs of focal infection. Malaria rapid diag-
nostic testing and blood cultures were negative; the urine
dipstick was normal. The patient had no underlying co-
morbidities reported and tested negative for HIV at inclu-
sion. Additionally, his mother reported an HIV-negative
result during routine prenatal screening. A diagnosis of
“presumed viral infection of unknown etiology” was
assigned. The patient did not receive any antimicrobials and
was asymptomatic by day 3 of follow-up.
In addition to the aforementioned HAstV, NGS also
detected a torque teno virus (TTV, 254 853 reads) (Fig. 1
and Supplementary Figure S1). HAstV-MLB1 presence
was conﬁrmed by real-time RT-PCR with a viral load
estimated at 2700 RNA copies/mL per the MLB1 assay
previously described7.
Case #2: a 3.5-year-old male presented with a 5-day
history of fever and cough. A past medical history of
untreated HIV infection and chronic malnutrition were
also documented. A temperature of 38.9 °C was measured
at triage accompanied by tachypnea but with normal
oxygen saturation (respiratory rate: 60 bpm, O2Sat: 99%).
Laboratory workup showed severe anemia (Hb 3.2 gm/dl),
and HIV infection was conﬁrmed by rapid test; however,
no CD4+T-cell counts were available. Malaria RDT and
blood cultures were negative, and the urine dipstick was
normal. C-reactive protein was measured at 80 mg/dL;
lactate was 3.5 mmol/L.
An initial diagnosis of “sepsis and severe anemia” was
assigned, and the patient was immediately hospitalized.
The hospital-based treatment included packed red blood
cells and presumptive antibiotic treatment with penicillin,
gentamicin, rifampicin, and ethambutol (based on clini-
cally suspected tuberculosis). During hospitalization, the
Fig. 1 Sample analysis ﬂowchart. Purple: NGS analyses. Orange: speciﬁc HAstV-MLB1 and HAstV-MLB2/MLB2-3 real-time RT-PCR conﬁrmation
assays. The number of reads for each speciﬁc virus detected by ezVIR is indicated. Read coverage histograms are shown for HAstV-MLB1 and HAstV-
MLB2. NGS next-generation sequencing, TTV torque teno virus, HIV-1 human immunodeﬁciency virus type 1, HHV-8 human herpesvirus 8, AAV adeno-
associated virus
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child developed progressive respiratory distress with
hypoxemia and clinical signs of liver failure with ascites
and jaundice. Penicillin/gentamicin was then changed to
co-trimoxazole and steroids due to a suspected Pneumo-
cystis jirovecii infection (no microbiological conﬁrmation
attempted). The patient died on the 8th day of hospitali-
zation. No autopsy was performed. Subsequent NGS
analysis on blood samples conﬁrmed the presence of HIV-
1 (27,044 reads), HHV-8 (2487 reads), adeno-associated
virus (40 reads), and TTV (3,245,696 reads; Fig. 1).
HAstV-MLB2 was conﬁrmed by real-time RT-PCR with a
viral load estimated at 72,000 RNA copies/mL using the
MLB2 and MLB2-3 assays previously described7,9. The
high viral load may suggest a potential association
between HAstV-MLB2 and the illness, especially without
an alternative diagnosis and no clinical response to
antibiotics.
The presence of a cough in Case #2 is consistent with
recent epidemiological data showing that upper respira-
tory tract manifestations were present in up to 70% of all
patients with novel HAstV (albeit in stool samples)7. This
association is also supported by our recent report on the
novel HAstV-VA1 detected in a nasopharyngeal swab of a
13-month-old child suffering from acute respiratory
symptoms15. Large-scale screening of novel and classical
HAstV in routine respiratory samples is needed to test the
signiﬁcance of this possible association. Interestingly,
neither Case #1 nor Case #2 presented signs or symptoms
of acute intestinal disease, which is known to be asso-
ciated with classical HAstV.
In conclusion, this study reports the ﬁrst description (to
our knowledge) of HAstV-MLB1 in a blood sample from a
patient with transient uncomplicated febrile disease. It is
also the ﬁrst description a HAstV-MLB2/HIV co-
infection. The high viral load and fatal outcome in the
latter case supports the rationale to investigate the
potential pathogenic role of novel HAstV in immuno-
compromised patients. Therefore, this study underscores
that novel HAstV may be implicated in various clinical
presentations, and implementing routine molecular assays
should be considered in susceptible populations.
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